在良性前列腺增生症中探索5-ARIs抵抗的:为个性化医学铺平道路
Zhemin Lin1, Zhanliang Liu1, Yinong Niu2
1Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
良性前列腺增生症 (BPH) 对5α减小酶抑制剂 (5-ARIs) 的治疗耐药性涉及表观遗传变化和炎症. 生物标志物和像GV1001这样的新疗法提供了个性化的BPH管理策略.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 良性前列腺增生症 (BPH) 通常使用5α减小酶抑制剂 (5-ARIs) 治疗.
- 一部分BPH患者对5-ARIs治疗没有有效的反应.
- 了解抵抗机制对于改善BPH管理至关重要.
研究的目的:
- 审查关于BPH中5-ARI耐药性机制的当前观点.
- 为了确定潜在的生物标志物来预测5-ARIs的响应性.
- 探索对抗5-ARI抗性BPH的新疗法选择.
主要方法:
- 关于BPH中5-ARIs耐药性的研究的综合文献综述.
- 分析涉及治疗不响应的分子途径.
- 评估新兴生物标志物和治疗剂.
主要成果:
- 5-ARI耐药性途径包括表观遗传修饰,荷尔蒙转变,自,雄激素受体变异和炎症.
- 生物标志物,如静脉前列腺突起,炎症因素和SNP可以预测治疗反应.
- 作为BPH的未来治疗选择,GV1001和mTOR抑制剂显示出希望.
结论:
- 不同的病理生理机制是BPH亚型和治疗耐药性的基础.
- 个性化医疗方法是必不可少的,超越标准的5-ARIs治疗.
- 早期识别治疗耐药性和风险分层将指导未来的BPH管理.
更多相关视频
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
